Effect of start age of breast cancer screening mammography on the risk of false-positive results
Por:
Salas, D, Ibanez, J, Roman, R, Cuevas, D, Sala, M, Ascunce, N, Zubizarreta, R, Castells, X and CFPR Cumulat False Posit Risk Grp
Fecha de Publicación:
01/07/2011
Resumen:
Objective. To estimate the false-positive (FP) risk according to the start age of mammography screening (45-46 or 50-51 years).
Method. Data from eight regions of the Spanish breast cancer screening programme from 1990 to 2006 were included (1,565,364 women). Discrete time-hazard models were used to ascertain the effect of age and time-related, programme-related and personal variables on FP leading to any further procedure and to invasive procedures (FPI). In a subset we estimated the differential FP risk of starting screening at 45-46 years (175.656 women) or 50-51 (251,275).
Results. A start age of 45-46 versus 50-51 years increased both FP (OR = 1.20: 95%Cl: 1.13-1.26) and FPI risks (OR = 1.43 (95%Cl: 1.18-1.73). Other factors increasing FP risk were premenopausal status (FP OR = 1.26: 95%Cl: 1.23-1.29 and FPI OR = 1.22; 95%Cl: 1.13-1.31), prior invasive procedures (FP OR = 1.52; 95%Cl: 1.47-1.57 and FPI (OR = 2.08; 95%Cl: 1.89-2.28) and family history (FP OR = 1.16: 95% Cl: 1.12-1.20 and FPI OR = 1.26; 95%Cl: 1.13-1.41). FP risk was increased by double reading (OR= 1.36: 95% Cl: 1.23-1.51) and FPI risk by double views (OR = 1.34; 95%Cl: 1.18-1.52). Both the cumulative FP and FPI risks were higher in women commencing screening at 45-46 years versus 50-51 years (33.30% versus 20.39% and 2.68% versus 1.76%).
Conclusions. Starting screening earlier increases the cumulative risk of FP and FPI. (C) 2011 Elsevier Inc. All rights reserved.
Direcciones
Salas, D:
DIRECCIÓN GENERAL DE SALUD PÚBLICA, Valencia, Spain; CENTRO SUPERIOR DE INVESTIGACIÓN EN SALUD PÚBLICA (CSISP), Valencia, Spain
Ibanez, J:
DIRECCIÓN GENERAL DE SALUD PÚBLICA, Valencia, Spain; CENTRO SUPERIOR DE INVESTIGACIÓN EN SALUD PÚBLICA (CSISP), Valencia, Spain
Roman, R:
CIBERESP, IM1M Parc Salut Mar, Dept Epidemiol & Evaluat, Barcelona 08003, Spain
Cuevas, D:
Valencian Hlth Agcy, Valencia 46010, Spain; Ctr Publ Hlth Res CS1SP, Valencia 46010, Spain
Ascunce, N:
CIBERESP, Inst Publ Hlth, Navarre Breast Canc Screening Programme, Pamplona 31003, Spain
Zubizarreta, R:
Hlth Off, Publ Hlth & Planning Directorate, Santiago 15781, Spain
Castells, X:
CIBERESP, IM1M Parc Salut Mar, Dept Epidemiol & Evaluat, Barcelona 08003, Spain
|